Skip to main content

Table 6 Long-term renal outcomes by treatment status

From: Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study

Patients, n (%) Never Discontinued
(n = 48)
Discontinued, Did Not Reinitiate
(n = 19)
Discontinued and Reinitiated
(n = 16)
All Discontinued
(n = 35)
Improved 17 (35) 2 (11) 0 (0) 2 (6)
Stable 20 (42) 15 (79) 4 (25) 19 (54)
Declined 11 (23) 2 (11) 12 (75) 14 (40)
  1. Note: For patients who never discontinued eculizumab, estimated glomerular filtration rate (eGFR) was compared at 6 months post-eculizumab initiation and at last follow-up. For patients who discontinued eculizumab, eGFR was compared at the time of discontinuation and at last follow-up. For patients who reinitiated eculizumab, eGFR prior to discontinuation and at last follow-up (post-reinitiation) was compared. Three patients who remained on eculizumab and seven patients who discontinued had missing data and were excluded from this analysis. Individual patient outcomes were assessed independently by the principal investigator and two additional authors. Findings were adjudicated by the principal investigator